Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers.
OBJECTIVE
To characterize the effects of levofloxacin on QT interval in healthy subjects and the most appropriate oral positive control treatments for International Conference on Harmonization (ICH) E14 QT/QTc studies.


METHODS
Healthy subjects received a single dose of levofloxacin (1000 or 1500 mg), moxifloxacin (400 mg) or placebo in a four-period crossover design. Digital 12-lead ECGs were recorded in triplicate. Measurement of QT interval was performed automatically with subsequent manual onscreen over-reading using electronic callipers. Blood samples were taken for determination of levofloxacin and moxifloxacin concentrations.


RESULTS
Mean QTcI (QT interval corrected for heart rate using a correction factor that is applicable to each individual) was prolonged in subjects receiving moxifloxacin 400 mg compared with placebo. The largest time-matched difference in QTcI for moxifloxacin compared with placebo was observed to be 13.19 ms (95% confidence interval 11.21, 15.17) at 3.5 h post dose. Prolonged mean QTcI was also observed in subjects receiving levofloxacin 1000 mg and 1500 mg compared with placebo. The largest time-matched difference in QTcI compared with placebo was observed at 3.5 h post dose for both 1000 mg and 1500 mg of levofloxacin [mean (95%) 4.42 ms (2.44, 6.39) in 1000 mg and 7.44 ms (5.47, 9.42) in 1500 mg]. A small increase in heart rate was observed with levofloxacin during the course of the study. However, moxifloxacin showed a greater increase compared with levofloxacin.


CONCLUSIONS
Both levofloxacin and moxifloxacin can fulfil the criteria for a positive comparator. The ICH E14 guidelines recommend a threshold of around 5 ms for a positive QT/QTc study. The largest time-matched difference in QTc for levofloxacin suggests the potential for use in more rigorous QT/QTc studies. This study has demonstrated the utility of levofloxacin on the assay in measuring mean QTc changes around 5 ms.
Taubel
Jorg
J
Richmond Pharmacology Ltd, St George's University of London, UK.
Naseem
Asif
A
Harada
Tomohiko
T
Wang
Duolao
D
Arezina
Radivoj
R
Lorch
Ulrike
U
Camm
A John
AJ
D000328:Adult; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D019540:Area Under Curve; D001372:Aza Compounds / Q000493:pharmacokinetics / Q000494:pharmacology*; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004562:Electrocardiography / Q000187:drug effects*; D005260:Female; D024841:Fluoroquinolones; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D064704:Levofloxacin; D008297:Male; D000077266:Moxifloxacin; D015242:Ofloxacin / Q000493:pharmacokinetics / Q000494:pharmacology*; D011804:Quinolines / Q000493:pharmacokinetics / Q000494:pharmacology*; D012015:Reference Standards; D055815:Young Adult
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D064704:Levofloxacin; D015242:Ofloxacin; D000077266:Moxifloxacin
J Antimicrob Chemother. 2002 Apr;49(4):593-6
11909831
Antimicrob Agents Chemother. 1998 Aug;42(8):2060-5
9687407
J Clin Pharmacol. 2004 May;44(5):464-73
15102866
Clin Pharmacol Ther. 2008 Oct;84(4):475-80
19238652
Clin Pharmacol Ther. 2003 Apr;73(4):292-303
12709719
Eur J Clin Pharmacol. 2007 Nov;63(11):1011-7
17891537
Fed Regist. 2005 Oct 20;70(202):61134-5
16237860
Ann Noninvasive Electrocardiol. 2006 Jan;11(1):52-6
16472283
South Med J. 2006 Jan;99(1):52-6
16466123
Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:68-75
18333868
Antimicrob Agents Chemother. 1997 Jul;41(7):1562-5
9210685
Clin Pharmacokinet. 2001;40(3):169-87
11327197
Br J Clin Pharmacol. 2008 Sep;66(3):396-404
18662287
Pharmacotherapy. 2001 Mar;21(3):301-19
11253855
Clin Pharmacol Ther. 2008 Jan;83(1):153-9
17581594
Ann Pharmacother. 2008 Jun;42(6):757-65
18445705
Heart Rhythm. 2005 Nov;2(2 Suppl):S23-9
16253928
Mol Pharmacol. 2001 Jan;59(1):122-6
11125032
Clin Pharmacol Ther. 2000 Dec;68(6):658-66
11180026
Pacing Clin Electrophysiol. 2004 Dec;27(12):1659-69
15613131
Antimicrob Agents Chemother. 2000 Oct;44(10):2600-3
10991830
Antimicrob Agents Chemother. 1999 Nov;43(11):2793-7
10543767
J Antimicrob Chemother. 1999 May;43 Suppl B:83-90
10382880
J Electrocardiol. 2004 Jan;37(1):25-9
15132366
Clin Ther. 2008 Feb;30(2):260-70
18343264
Clin Pharmacol Ther. 2007 Mar;81(3):377-85
17339867